T. Rowe Price Associates
BBNX

T. Rowe Price Associates’s Beta Bionics BBNX Stock Holding History

T. Rowe Price Associates’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Buy
43,450
+7,978
+22% +$94.9K ﹤0.01% 2481
2026
Q1 		$356K Sell
35,472
-497,277
-93% -$7.36M ﹤0.01% 2602
2025
Q4 		$16.2M Buy
532,749
+45,091
+9% +$1.2M ﹤0.01% 1116
2025
Q3 		$9.69M Buy
487,658
+169,715
+53% +$2.98M ﹤0.01% 1237
2025
Q2 		$4.63M Sell
317,943
-318,261
-50% -$4.51M ﹤0.01% 1294
2025
Q1 		$7.79M Buy
+636,204
New +$11.9M ﹤0.01% 1159

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

T. Rowe Price Associates's BBNX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Beta Bionics (BBNX) stake by 22% in Q2 2026, buying an estimated $94.9K and bringing the position to 43,450 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

T. Rowe Price Associates first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $16.2M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • T. Rowe Price Associates held 43,450 shares of Beta Bionics worth $681K as of Q2 2026.
  • T. Rowe Price Associates bought 7,978 Beta Bionics shares in Q2 2026, an estimated $94.9K.
  • Beta Bionics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2481 holding.
  • T. Rowe Price Associates first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • T. Rowe Price Associates's Beta Bionics position peaked at $16.2M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.